POSB93 Conversion from Subcutaneous Trastuzumab to Trastuzumab-Dkst in Metastatic Breast Cancer: Comparative Cost-Efficiency Modelling between US and France
Abstract
Authors
K MacDonald I Abraham A Fuentes-Alburo H Austrup J Möbius